Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Amphiregulin confers trastuzumab resistance via AKT and ERK activation in HER2-positive breast cancer.

Journal of cancer research and clinical oncology - 1 Jan 2016

Kim Ji-Won, Kim Debora K, Min Ahrum, Lee Kyung-Hun, Nam Hyun-Jin, Kim Jee Hyun, Kim Jin-Soo, Kim Tae-Yong, Im Seock-Ah, Park In Ae

Abstract excerpt

PURPOSE: Human epidermal growth factor receptor 2 (HER2) heterodimerizes and shares common signaling pathways with epidermal growth factor receptor (EGFR). In this study, we investigated the clinical implication of amphiregulin, a ligand for EGFR, on trastuzumab therapy in HER2-positive breast cancer. METHODS: Serum amphiregulin levels were quantified in 50 consecutive patients with HER2-positive metastatic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to Extracellular Signal-Regulated MAP Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunoenzyme Techniques

Share to Neoplasm Staging

Share to Proto-Oncogene Proteins c-akt

Share to Receptor, ErbB-2

Share to Survival Rate

Share to Trastuzumab

Source

Identifiers

PMID: 26195282
DOI: 10.1007/s00432-015-2012-4

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Amphiregulin confers trastuzumab resistance via AKT and ERK activation in HER2-positive breast cancer.PMID 26195282Read ↗

Annexin A2 and its downstream IL-6 and HB-EGF as secretory biomarkers in the differential diagnosis of Her-2 negative breast cancer.Semantic proximity Read ↗

Reciprocal regulation of annexin A2 and EGFR with Her-2 in Her-2 negative and herceptin-resistant breast cancer.Semantic proximity Read ↗

Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.Semantic proximity Read ↗

Antisense expression for amphiregulin suppresses tumorigenicity of a transformed human breast epithelial cell line.Semantic proximity Read ↗

Selection and Characterization of Her2 Binding-designed Ankyrin Repeat ProteinsSemantic proximity Read ↗

Knock-down of amphiregulin inhibits cellular invasion in inflammatory breast cancer.Semantic proximity Read ↗

A functional screen for genes inducing epidermal growth factor autonomy of human mammary epithelial cells confirms the role of amphiregulin.Semantic proximity Read ↗

Association of amphiregulin with the cetuximab sensitivity of gastric cancer cell lines.Semantic proximity Read ↗

Amphiregulin deletion strongly attenuates the development of estrogen receptor-positive tumors in p53 mutant mice.Semantic proximity Read ↗

HER4 Mediates Ligand-Dependent Antiproliferative and Differentiation Responses in Human Breast Cancer CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.